🚀 VC round data is live in beta, check it out!
Artrya Valuation Multiples
Discover revenue and EBITDA valuation multiples for Artrya and similar public comparables like EM Systems Co., Medley Inc., Echo IQ, Vitalhub and more.
Artrya Overview
About Artrya
Artrya Ltd is a medical technology company. The company is engaged in the development and commercialization of Artrya Salix, its patented artificial intelligence platform that detects, diagnoses, and helps address coronary artery disease. It is managed based on a single segment, being the development of AI-driven CCTA image analysis technology.
Founded
2018
HQ
Employees
43
Website
Sectors
Financials (LTM)
EV
$327M
Artrya Financials
Artrya reported last 12-month revenue of $5M and negative EBITDA of ($10M).
In the same LTM period, Artrya generated $5M in gross profit, ($10M) in EBITDA losses, and had net loss of ($11M).
Revenue (LTM)
Artrya P&L
In the most recent fiscal year, Artrya reported revenue of $20K and EBITDA of ($10M).
Artrya expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $5M | XXX | $20K | XXX | XXX | XXX |
| Gross Profit | $5M | XXX | $20K | XXX | XXX | XXX |
| Gross Margin | 100% | XXX | 100% | XXX | XXX | XXX |
| EBITDA | ($10M) | XXX | ($10M) | XXX | XXX | XXX |
| EBITDA Margin | (201%) | XXX | (48861%) | XXX | XXX | XXX |
| EBIT Margin | (218%) | XXX | (55376%) | XXX | XXX | XXX |
| Net Profit | ($11M) | XXX | ($11M) | XXX | XXX | XXX |
| Net Margin | (216%) | XXX | (53441%) | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Artrya Stock Performance
Artrya has current market cap of $335M, and enterprise value of $327M.
Market Cap Evolution
Artrya's stock price is $2.21.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $327M | $335M | 0.0% | XXX | XXX | XXX | $-0.07 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialArtrya Valuation Multiples
Artrya trades at 63.7x EV/Revenue multiple, and (31.7x) EV/EBITDA.
EV / Revenue (LTM)
Artrya Financial Valuation Multiples
As of March 23, 2026, Artrya has market cap of $335M and EV of $327M.
Equity research analysts estimate Artrya's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Artrya has a P/E ratio of (30.2x).
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $335M | XXX | $335M | XXX | XXX | XXX |
| EV (current) | $327M | XXX | $327M | XXX | XXX | XXX |
| EV/Revenue | 63.7x | XXX | 16569.6x | XXX | XXX | XXX |
| EV/EBITDA | (31.7x) | XXX | (33.9x) | XXX | XXX | XXX |
| EV/EBIT | (29.3x) | XXX | (29.9x) | XXX | XXX | XXX |
| EV/Gross Profit | 63.7x | XXX | 16569.6x | XXX | XXX | XXX |
| P/E | (30.2x) | XXX | (31.7x) | XXX | XXX | XXX |
| EV/FCF | (31.7x) | XXX | (33.9x) | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Artrya Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Artrya Margins & Growth Rates
Artrya's revenue in the last 12 month grew by 107%.
Artrya's revenue per employee in the last FY averaged $0.1M.
Artrya's rule of 40 is (94%) (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Artrya's rule of X is 67% (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
Artrya Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 107% | XXX | 35551% | XXX | XXX | XXX |
| EBITDA Margin | (201%) | XXX | (48861%) | XXX | XXX | XXX |
| EBITDA Growth | (28%) | XXX | 9% | XXX | XXX | XXX |
| Rule of 40 | — | XXX | (94%) | XXX | XXX | XXX |
| Bessemer Rule of X | — | XXX | 67% | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.1M | XXX | XXX | XXX |
| S&M Expenses to Revenue | — | XXX | 182% | XXX | XXX | XXX |
| G&A Expenses to Revenue | — | XXX | 37561% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 78964% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Artrya Public Comps
See public comps and valuation multiples for other Healthcare Software comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| EM Systems Co. | XXX | XXX | XXX | XXX | XXX | XXX |
| Medley Inc. | XXX | XXX | XXX | XXX | XXX | XXX |
| Echo IQ | XXX | XXX | XXX | XXX | XXX | XXX |
| Vitalhub | XXX | XXX | XXX | XXX | XXX | XXX |
| Kneat | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Artrya M&A Activity
Artrya acquired XXX companies to date.
Last acquisition by Artrya was on XXXXXXXX, XXXXX. Artrya acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Artrya
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialArtrya Investment Activity
Artrya invested in XXX companies to date.
Artrya made its latest investment on XXXXXXXX, XXXXX. Artrya invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Artrya
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Artrya
| When was Artrya founded? | Artrya was founded in 2018. |
| Where is Artrya headquartered? | Artrya is headquartered in Australia. |
| How many employees does Artrya have? | As of today, Artrya has over 43 employees. |
| Is Artrya publicly listed? | Yes, Artrya is a public company listed on Australian Securities Exchange. |
| What is the stock symbol of Artrya? | Artrya trades under AYA ticker. |
| When did Artrya go public? | Artrya went public in 2021. |
| Who are competitors of Artrya? | Artrya main competitors are EM Systems Co., Medley Inc., Echo IQ, Vitalhub. |
| What is the current market cap of Artrya? | Artrya's current market cap is $335M. |
| What is the current revenue of Artrya? | Artrya's last 12 months revenue is $5M. |
| What is the current revenue growth of Artrya? | Artrya revenue growth (NTM/LTM) is 107%. |
| What is the current EV/Revenue multiple of Artrya? | Current revenue multiple of Artrya is 63.7x. |
| Is Artrya profitable? | No, Artrya is not profitable. |
| What is the current EBITDA of Artrya? | Artrya has negative EBITDA and is not profitable. |
| What is Artrya's EBITDA margin? | Artrya's last 12 months EBITDA margin is (201%). |
| What is the current EV/EBITDA multiple of Artrya? | Current EBITDA multiple of Artrya is (31.7x). |
| What is the current FCF of Artrya? | Artrya's last 12 months FCF is ($10M). |
| What is Artrya's FCF margin? | Artrya's last 12 months FCF margin is (201%). |
| What is the current EV/FCF multiple of Artrya? | Current FCF multiple of Artrya is (31.7x). |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.